We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-21.77%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$293M
AUM Growth
-$387M
Cap. Flow
-$274M
Cap. Flow %
-93.57%
Top 10 Hldgs %
94.22%
Holding
15
New
1
Increased
9
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$5.68M
2
MRUS
Merus
MRUS
+$4.5M
3
ARVN icon
Arvinas
ARVN
+$3.84M
4
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$1.77M
5
GMAB icon
Genmab
GMAB
+$1.53M

Top Sells

Rank Stock Value
1
FDMT icon
4D Molecular Therapeutics
FDMT
+$8.69M
2
BPMC
Blueprint Medicines
BPMC
+$3.81M

Sector Composition

Rank Sector Weight
1 Healthcare 80.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$55.7M 19.01%
+750,000
New +$56.3M
ARWR icon
2
Arrowhead Research
ARWR
$12.4B
$42.2M 14.4%
1,198,515
+151,075
+14% +$5.68M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$36.2M 12.35%
716,539
-65,000
-8% -$3.81M
MRUS
4
DELISTED
Merus
MRUS
$33.4M 11.41%
1,477,109
+215,575
+17% +$4.5M
ARVN icon
5
Arvinas
ARVN
$572M
$32.5M 11.09%
771,745
+76,498
+11% +$3.84M
RGNX icon
6
Regenxbio
RGNX
$708M
$28.8M 9.84%
1,167,684
+49,000
+4% +$1.22M
QURE icon
7
uniQure
QURE
$3.22B
$18.1M 6.18%
971,490
+70,000
+8% +$1.11M
AMYT
8
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$13M 4.45%
1,866,652
+226,652
+14% +$1.77M
ARGX icon
9
argenx
ARGX
$54.1B
$9.09M 3.1%
24,000
– –
PVLA
10
Palvella Therapeutics
PVLA
$2.27B
$6.99M 2.38%
46,704
+343
+0.7% +$62.6K
GMAB icon
11
Genmab
GMAB
$19.5B
$6.98M 2.38%
214,848
+47,348
+28% +$1.53M
FDMT icon
12
4D Molecular Therapeutics
FDMT
$562M
$6.01M 2.05%
861,607
-893,899
-51% -$8.69M
SPRO icon
13
Spero Therapeutics
SPRO
$73M
$3.94M 1.35%
5,321,231
+39,727
+0.8% +$116K
SPY icon
14
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
– –
-350,000
Closed -$158M
XBI icon
15
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-2,000,000
Closed -$180M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Aquilo Capital Management held 15 positions worth $293M, down 57% from $680M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Aquilo Capital Management withdrew a net $274M in Q2 2022, closing 2 positions and reducing 2 holdings. Its largest reduction was 4D Molecular Therapeutics, cutting an estimated $8.69M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 50% a quarter earlier.

Against the trend, Aquilo Capital Management added an estimated $5.68M to Arrowhead Research.

  • Aquilo Capital Management added most to Arrowhead Research in Q2 2022, an estimated $5.68M increase.
  • Aquilo Capital Management's biggest Q2 2022 reduction was 4D Molecular Therapeutics, cutting an estimated $8.69M.
  • Aquilo Capital Management's ten largest holdings make up 94% of its $293M portfolio in Q2 2022.
  • Aquilo Capital Management opened 1 new position and closed 2 in Q2 2022.
  • Aquilo Capital Management's portfolio value fell 57% quarter-over-quarter to $293M.

Based on Aquilo Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.